Biomarkers, Diagnostics and Precision Medicine in the Drug Industry
Critical Challenges, Limitations and Roadmaps for the Best Practices
- Publisher's listprice EUR 132.00
-
54 747 Ft (52 140 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 10% (cc. 5 475 Ft off)
- Discounted price 49 272 Ft (46 926 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
54 747 Ft
Availability
printed on demand
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher Elsevier Science
- Date of Publication 11 June 2019
- ISBN 9780128161210
- Binding Paperback
- No. of pages294 pages
- Size 276x215 mm
- Weight 750 g
- Language English 0
Categories
Long description:
The high failure rate in the pharmaceutical industry has positioned biomarkers and personalized medicine in the frontline, as possible solutions. If executed right, biomarkers and companion diagnostics (CDx) can potentially help the drug industry enhance the probability of success, accelerate the time to market, and, more importantly, benefit patients by supporting accurate diagnosis and selection of the most effective and least toxic therapies. This book aims to examine the challenges and limitations in biomarkers and laboratory tests. It also offers advice on best practices to ensure proper application of biomarkers and bridges the gap between diagnostic business development claims and real-life deliverables. The book covers biomarkers for different purposes, provides examples from different technologies, which includes standard-of-care approved assays as well as for-investigational-use and for-research-use-only assays. It also includes new data for biomarkers in different therapeutic indications and offers case studies and practical examples.
This book serves as a reference to drug developers, IVD providers, clinical labs, healthcare givers, academicians, and researchers for best practices to help increase the probability of success in drug development and improve patient management.
MoreTable of Contents:
1. Pharmaceutical crisis2. Applications of biomarkers for different purposes in drug development 3. Pharmacogenetics of therapeutics4. Precision medicine and companion diagnostics in drug development5. Essential attributes of an acceptable in-vitro diagnostic test6. Fundamentals of Assay Development and Validation7. Essentials of Laboratory Quality Management8. Biological variables and their potential impact on biomarkers and precision medicine initiative9. Pre-analytical Variables and their potential impact on biomarkers and precision medicine initiative10. Analytical Discrepancies and their potential impact on biomarkers and precision medicine initiative11. Road Map to Best Practices
More
